Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference Oct 13, 2022
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022 Oct 12, 2022
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Oct 3, 2022
Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone Sep 21, 2022
Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone Aug 30, 2022
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility Aug 8, 2022
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022 Aug 8, 2022
Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770 Jul 5, 2022
